Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788879 | 0.73 | KCNA4 (0.30) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL11971096 | 0.73 | — | — | |
| SCHEMBL17761458 | 0.71 | KCNA4 (0.33) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL2894816 | 0.71 | — | — | |
| SCHEMBL28149512 | 0.69 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1487068 | 0.69 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL17616467 | 0.69 | — | — | |
| SCHEMBL16468822 | 0.65 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL17616534 | 0.63 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL15199621 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2009054887-A1 | PROCESS FOR PREPARING AN ANTI-HYPERCHOLESTEROLEMIC COMPOUND | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ALDH1A1 372/4885KCNA4 3804/4885KCNA1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.